| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H12FN3O3S |
| Molecular Weight | 309.316 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(NC(=O)NC2=CC=C(F)C=C2)C=C1
InChI
InChIKey=YJQZNWPYLCNRLP-UHFFFAOYSA-N
InChI=1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)
U-104 is an inhibitor of CA IX that binds only to CA IX under hypoxic conditions in vivo. The binding results in significant inhibition of tumor growth and metastasis formation in both spontaneous and experimental models of metastasis. U-104 reduces the medium acidity by inhibiting the catalytic activity of the CA IX. It binds specifically only to hypoxic cells expressing CA IX.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
4T1 cells were implanted orthotopically into Balb/c mice and treatment was initiated after tumors were established.U-104 was solubilized in 55.6% PEG 400, 11.1% ethanol and 33% water at 5 mg/ml, and then administered as oral gavage. In separate experiment MDA-MB-231 LM2-4Lucю cells were implanted into NOD/SCID mice, tumors were established and treatment was initiated. Paclitaxel was administered by i.v. injection and U-104 was provided by intraperitoneal (i.p.) injection according to the dosing schedule.
Route of Administration:
Other
ACTIVE MOIETY
